Form 4: Director Jason Nunn Receives Zenas BioPharma Stock Options

Director Jason Nunn was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Summary

• Director Jason R. Nunn acquired 18,500 stock options in Zenas BioPharma, Inc. (ZBIO).
• The options have an exercise price of $18.71 per share.
• The grant date for these options is June 15, 2026.
• The options are set to expire on June 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest 100% on June 15, 2027, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of key leadership.

Comparison to Industry Standards

• The grant of stock options with a one-year cliff vesting period is consistent with standard corporate governance practices for board members in mid-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 15, 2027.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, Insider Trading, Stock Options, Director Compensation